CN105919998B - 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂 - Google Patents

用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂 Download PDF

Info

Publication number
CN105919998B
CN105919998B CN201610246787.9A CN201610246787A CN105919998B CN 105919998 B CN105919998 B CN 105919998B CN 201610246787 A CN201610246787 A CN 201610246787A CN 105919998 B CN105919998 B CN 105919998B
Authority
CN
China
Prior art keywords
compound
group
acid pump
atom
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610246787.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105919998A (zh
Inventor
高桥伸行
小泉信一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of CN105919998A publication Critical patent/CN105919998A/zh
Application granted granted Critical
Publication of CN105919998B publication Critical patent/CN105919998B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201610246787.9A 2009-07-09 2010-07-09 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂 Active CN105919998B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009163182 2009-07-09
JP2009-163182 2009-07-09
JP2009188464 2009-08-17
JP2009-188464 2009-08-17
CN2010800308648A CN102470126A (zh) 2009-07-09 2010-07-09 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800308648A Division CN102470126A (zh) 2009-07-09 2010-07-09 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂

Publications (2)

Publication Number Publication Date
CN105919998A CN105919998A (zh) 2016-09-07
CN105919998B true CN105919998B (zh) 2021-08-24

Family

ID=43429307

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610246787.9A Active CN105919998B (zh) 2009-07-09 2010-07-09 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
CN2010800308648A Pending CN102470126A (zh) 2009-07-09 2010-07-09 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800308648A Pending CN102470126A (zh) 2009-07-09 2010-07-09 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂

Country Status (11)

Country Link
US (1) US8648080B2 (https=)
EP (1) EP2452680B1 (https=)
JP (4) JP5802898B2 (https=)
KR (1) KR101605063B1 (https=)
CN (2) CN105919998B (https=)
BR (1) BRPI1013288A2 (https=)
CA (1) CA2765529C (https=)
ES (1) ES2767251T3 (https=)
MX (1) MX2012000275A (https=)
RU (1) RU2586276C2 (https=)
WO (1) WO2011004882A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3071206T3 (da) 2013-11-22 2021-05-25 CL BioSciences LLC Gastrinantagonister (eg yf476, netazepid) til behandling og forebyggelse af osteoporose
CN105708812A (zh) * 2014-12-02 2016-06-29 江苏柯菲平医药股份有限公司 一种5-（2-氟苯基）-n-甲基-1-（3-吡啶基磺酰基）-1h-吡咯-3-甲氨冻干粉针及其制备方法
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
MA41850A (fr) * 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
MX374972B (es) 2015-06-08 2025-03-06 Hk Inno N Corp Uso de derivados de bencimidazol para escape acido nocturno.
CN105078891B (zh) * 2015-08-20 2018-04-24 寿光富康制药有限公司 一种tak-438脂质体及其制备方法和应用
CN105168131B (zh) * 2015-09-17 2018-04-24 寿光富康制药有限公司 一种tak-438纳米乳的制备方法
CN106913859B (zh) * 2015-12-25 2021-05-11 中美华世通生物医药科技(武汉)股份有限公司 药物组合物及制备方法
CN105663096B (zh) * 2016-01-25 2019-06-14 南京济群医药科技股份有限公司 一种沃诺拉赞口腔速溶膜剂及其制备方法
KR101829706B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN112933091B (zh) * 2020-09-07 2023-01-06 天地恒一制药股份有限公司 一种抗胃酸类疾病的药物组合物及应用
AU2021364255B2 (en) * 2020-10-23 2025-02-13 Hk Inno.N Corporation Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof
JP7566164B2 (ja) * 2020-12-30 2024-10-11 エイチケー イノ．エヌ コーポレーション テゴプラザンおよび非ステロイド性抗炎症薬を含有する医薬組成物
CN118355013A (zh) * 2021-12-08 2024-07-16 制药基因科学株式会社 苯并咪唑衍生物化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005177A1 (en) * 1994-08-13 1996-02-22 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
WO1999055706A1 (en) * 1998-04-29 1999-11-04 Astrazeneca Ab Imidazo pyridine derivatives which inhibit gastric acid secretion
WO2007026916A1 (en) * 2005-08-30 2007-03-08 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
CN101341149A (zh) * 2005-12-19 2009-01-07 辉瑞大药厂 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5996272A (ja) 1982-11-26 1984-06-02 Isuzu Motors Ltd 金属表面の強化層形成方法
TW282460B (https=) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
SE9802794D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
EE04677B1 (et) * 1998-09-23 2006-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahdropridoeetrid, nende kasutamine ja ravim
JP2002528548A (ja) 1998-11-03 2002-09-03 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング イミダゾナフチリジン
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
TWI287014B (en) 1999-06-15 2007-09-21 Sankyo Co Optically active pyrrolopyridazine compound
KR100860627B1 (ko) 2000-03-29 2008-09-29 니코메드 게엠베하 이미다조피리딘 유도체의 프로드러그
CA2425363A1 (en) 2000-10-12 2003-04-10 Fumihiko Sato Benzimidazole compounds, process for producing the same and use thereof
MXPA04001277A (es) 2001-08-10 2004-05-27 Altana Pharma Ag Imidazopiridinas triciclicas.
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
CA2506027A1 (en) 2002-11-19 2004-06-03 Altana Pharma Ag 8-substituted imidazopyridines
AR043063A1 (es) 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
CN100393720C (zh) 2003-04-04 2008-06-11 奥坦纳医药公司 环苯并咪唑化合物
JP2006528231A (ja) 2003-05-27 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
SE0301905D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound I with therapeutic effect
BRPI0414046A (pt) 2003-08-29 2006-10-24 Dynogen Pharmaceuticals Inc método de tratamento de um distúrbio de motilidade gastrintestinal, de tratamento de "gerd", de "gerd" noturno, composição farmacêutica, kit que compreende um composto e método para aumentar a motilidade esofágica em um paciente
WO2005026164A1 (en) 2003-09-18 2005-03-24 Altana Pharma Ag Pharmacologically active imidazo[4,5-c]pyridines
AR046893A1 (es) 2003-12-16 2005-12-28 Altana Pharma Ag Bencimidazoles triciclicos
AR046941A1 (es) 2003-12-19 2006-01-04 Altana Pharma Ag Imidazopiridinas triciclicas y su uso como inhibidores de secrecion de acido gastrico
US20080033006A1 (en) 2004-01-26 2008-02-07 Altana Pharma Ag 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors
EP1718646A1 (en) 2004-02-18 2006-11-08 Altana Pharma AG 1,2,4-triazolo[4,3-a]pyridines useful in the treatment of gastrointestinal disorders
US20070191334A1 (en) 2004-03-17 2007-08-16 Altana Pharma Ag Tricyclic imidazopyridines
AR048869A1 (es) 2004-04-26 2006-06-07 Altana Pharma Ag Bencimidazoles triciclicos
DE602005002751T2 (de) 2004-06-09 2008-07-17 Nycomed Gmbh Substituierte tricyclische benzimidazole
MX2007002214A (es) 2004-09-03 2007-05-07 Yuhan Corp Derivados de pirrolo[3,2-c]piridina y procesos para su preparacion.
ATE466013T1 (de) 2004-09-03 2010-05-15 Yuhan Corp Pyrroloä3,2-cüpyridinderivate und verfahren zu deren herstellung
DK1784404T3 (da) 2004-09-03 2012-02-13 Yuhan Corp Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
WO2006037748A1 (en) 2004-10-01 2006-04-13 Altana Pharma Ag Substituted tricyclic benzimidazoles
AR051041A1 (es) 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
AR051375A1 (es) 2004-10-15 2007-01-10 Altana Pharma Ag Imidazopiridinas difluoro substituidas
CA2589448A1 (en) 2004-12-09 2006-06-15 Altana Pharma Ag Substituted imidazo[4,5-b]pyridines as inhibitors of gastric acid secretion
KR101122376B1 (ko) 2005-03-09 2012-03-26 주식회사유한양행 신규의 5,6-다이메틸피리미딘 유도체 및 그의 제조방법
KR101137168B1 (ko) 2005-03-09 2012-04-19 주식회사유한양행 피롤로［２,３-ｄ］피리다진 유도체 및 그의 제조방법
PE20061110A1 (es) 2005-03-24 2006-10-20 Glaxo Group Ltd Derivados de imidazopiridina como antagonistas de la bomba de acido (apa)
EP1863820A1 (en) 2005-03-24 2007-12-12 Nycomed GmbH Thioamide-substituted tricyclic benzimidazoles useful for the treatment of gastrointestinal diseases
CA2601381A1 (en) 2005-03-24 2006-09-28 Nycomed Gmbh 6-thioamide substituted benzimidazoles
AU2006243255A1 (en) 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use us antiinflammatory agents with gastrointestinal protective activity
AR057061A1 (es) 2005-06-16 2007-11-14 Altana Pharma Ag Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos
WO2006136552A2 (en) 2005-06-22 2006-12-28 Nycomed Gmbh Process for the production of intermadiates for the preparation of tricyclic benzimidazoles
GB0513423D0 (en) 2005-06-30 2005-08-03 Glaxo Group Ltd Novel compounds
EP1926714A1 (en) 2005-08-22 2008-06-04 Nycomed GmbH Isotopically substituted benzimidazole derivatives
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
WO2007114338A1 (ja) 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
WO2008015196A1 (en) 2006-07-31 2008-02-07 Nycomed Gmbh 5-,7-bis-substituted imidazo[1,2-a]pyridines
ATE512969T1 (de) 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
WO2008058990A1 (en) 2006-11-16 2008-05-22 Nycomed Gmbh 7,7-disubstituted pyrano-[2,3-c]-imidazo-[1,2-a]-pyridine derivatives and their use as gastric acid secretion inhibitors
WO2008071766A2 (en) 2006-12-14 2008-06-19 Nycomed Gmbh Spiro-indene substituted imidazonaphythyridine and pyranoimidazopyridine derivatives as inhibitors of gastric acid secretion
WO2008071765A1 (en) 2006-12-14 2008-06-19 Nycomed Gmbh Pharmaceutically active spiro-substituted benzimidazole derivatives
WO2008084067A2 (en) 2007-01-12 2008-07-17 Nycomed Gmbh Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives
WO2008095912A2 (en) 2007-02-06 2008-08-14 Nycomed Gmbh Enantiopure pharmacologically active tricyclic benzimidazoles
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2008151927A2 (en) 2007-06-15 2008-12-18 Nycomed Gmbh 6-n-substituted benz imidazole derivatives as acid pump antagonists
WO2009041705A2 (en) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds as proton pump inhibitors
WO2009041447A1 (ja) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited ５員複素環化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005177A1 (en) * 1994-08-13 1996-02-22 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
WO1999055706A1 (en) * 1998-04-29 1999-11-04 Astrazeneca Ab Imidazo pyridine derivatives which inhibit gastric acid secretion
WO2007026916A1 (en) * 2005-08-30 2007-03-08 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
CN101341149A (zh) * 2005-12-19 2009-01-07 辉瑞大药厂 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Inhibition of phase III activity by acid in canine stomach";Yugo Matsunaga et.al.;《Regulatory Peptides》;19941231;第52卷(第1期);摘要,第66页左栏第10行－第67页左栏第3行 *

Also Published As

Publication number Publication date
JP5699309B2 (ja) 2015-04-08
CN105919998A (zh) 2016-09-07
RU2586276C2 (ru) 2016-06-10
JP2016166255A (ja) 2016-09-15
CN102470126A (zh) 2012-05-23
EP2452680B1 (en) 2019-12-18
JPWO2011004882A1 (ja) 2012-12-20
JP6212765B2 (ja) 2017-10-18
KR101605063B1 (ko) 2016-03-21
JP2013144719A (ja) 2013-07-25
CA2765529C (en) 2017-02-07
RU2012104533A (ru) 2013-08-20
JP5978447B2 (ja) 2016-08-24
EP2452680A1 (en) 2012-05-16
KR20120052269A (ko) 2012-05-23
HK1225608A1 (zh) 2017-09-15
JP2015038140A (ja) 2015-02-26
WO2011004882A1 (ja) 2011-01-13
CA2765529A1 (en) 2011-01-13
US8648080B2 (en) 2014-02-11
EP2452680A4 (en) 2013-12-04
BRPI1013288A2 (pt) 2016-03-29
US20120115820A1 (en) 2012-05-10
ES2767251T3 (es) 2020-06-17
JP5802898B2 (ja) 2015-11-04
MX2012000275A (es) 2012-02-08

Similar Documents

Publication Publication Date Title
CN105919998B (zh) 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
US20090227633A1 (en) Methods to inhibit tumor cell growth by using proton pump inhibitors
JP2003523324A5 (https=)
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
TW201219372A (en) Compositions and methods of treating pulmonary hypertension
JP2020516591A (ja) Ｍｏｒアゴニストおよびｋｏｒアゴニストを含有する医薬組成物、およびその用途
EA029000B1 (ru) КОМБИНАЦИЯ БОРТЕЗОМИДА И Akt-ИНГИБИТОРА ДЛЯ ЛЕЧЕНИЯ МНОЖЕСТВЕННОЙ МИЕЛОМЫ
WO2012011840A1 (ru) Циклические ν,ν'-диарилтиомочевины и ν,ν'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения
WO2013175805A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
HK1204286B (en) Ghrelin receptor agonists for the treatment of achlorhydria
EP4301371A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
HK1168297A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement
RU2002107421A (ru) Алкоксизамещенные бензимидазольные соединения, содержащие их фармацевтические препараты и способы их применения
HK1169037B (en) Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
HK1169037A (en) Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
TW200901984A (en) A medicine for treating or preventing alzheimer's disease
HK40105245A (zh) 用於治疗肉瘤的取代的3，6-二氢-2h-1，3，4-恶二嗪-2-酮

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225608

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant